U.S. Supporting TRIPS Waiver for Vaccines
U.S. Trade Representative Katherine Tai announced May 5 that the U.S. will support an intellectual property waiver for COVID-19 vaccines, but cautioned that negotiating the language in Geneva will take time, because of the need for consensus at the World…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
Trade Organization, and because of the “complexity of the issues.” Top Democrats in Congress welcomed the announcement. Tai also said the administration will work to increase production of raw materials for vaccines, which has been the constraint so far for Indian vaccine manufacturers. Pfizer has expressed interest in manufacturing in India if it would speed approval of its vaccine; India currently does not allow imports of Johnson & Johnson, Pfizer or Moderna vaccines.